Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high‐risk grade 2 glioma: An analysis of the National Cancer Data Base

BACKGROUND The addition of chemotherapy to adjuvant radiotherapy (chemotherapy and radiation therapy [CRT]) improves overall survival (OS) for patients with high‐risk grade 2 gliomas; however, the impact of chemotherapy alone (CA) is unknown. This study compares the OS of patients with high‐risk gra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2018-03, Vol.124 (6), p.1169-1178
Hauptverfasser: Jhaveri, Jaymin, Liu, Yuan, Chowdhary, Mudit, Buchwald, Zachary S., Gillespie, Theresa W., Olson, Jeffrey J., Voloschin, Alfredo D., Eaton, Bree R., Shu, Hui‐Kuo G., Crocker, Ian R., Curran, Walter J., Patel, Kirtesh R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND The addition of chemotherapy to adjuvant radiotherapy (chemotherapy and radiation therapy [CRT]) improves overall survival (OS) for patients with high‐risk grade 2 gliomas; however, the impact of chemotherapy alone (CA) is unknown. This study compares the OS of patients with high‐risk grade 2 gliomas treated with CA versus CRT. METHODS Patients with high‐risk grade 2 gliomas (subtotal resection or age ≥ 40 years) with oligodendrogliomas, astrocytomas, or mixed tumors were identified with the National Cancer Data Base. Patients were grouped into CA and CRT cohorts. Univariate analyses and multivariate analyses (MVAs) were performed. Propensity score (PS) matching was also implemented. The Kaplan‐Meier method was used to analyze OS. RESULTS A total of 1054 patients with high‐risk grade 2 gliomas were identified: 496 (47.1%) received CA, and 558 (52.9%) received CRT. Patients treated with CA were more likely (all P values  6 cm, astrocytoma histology, and older age were predictors for worse OS (all P values 
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.31158